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GenderNon-tuberculous mycobacteria (NTM) are environmental microbes that cause a variety of
diseases both in immunocompromised and immunocompetent patients. Epidemiologic
data indicate that there has been a global rise in the incidence of NTM infections. It has also
been noted that NTM infections have a predilection to occur in postmenopausal women. In
a recent study, it was demonstrated that in patients with non-CF bronchiectasis the prob-
ability of NTM isolation was significantly higher in elderly female patients and in those
with a low body mass index. However, the mechanisms of causality of these gender differ-
ences and morpho-phenotypes remain enigmatic. The present study reviews the data and
plausible mechanismswhichmight provide clues to this gender susceptibility andmorpho-
phenotypes of patients with bronchiectasis and NTM.
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Nontuberculous mycobacteria (NTM) are environmental
microbes that cause a variety of diseases, including chronic
lung infections. NTM are normal inhabitants of soil and
drinking water and hence are typically acquired from these
sources. Similar to TB, NTM can infect any organ system.
However, pulmonary infections, lymphadenitis and skin and
soft tissue infections are the most common. Epidemiologic
data suggest that there has been a rise in the incidence and
prevalence of NTM infections and importantly NTM-related
death numbers over the past decade [1]. Some studies suggest
that the incidence of NTM is as high as 15.5 cases per 100,000
in persons over 50 years of age in the United States [2–4]. This
increase has been attributed to improvements in investigative
methodologies such as 16S rNA gene sequencing to detect the
presence of mycobacteria and awareness of the importance of
NTM species as human pathogens [5,6]. Several studies have
attempted to define the phenotypic characteristics of patients
with NTM. Immunocompromised patients are particularly
vulnerable and develop disseminated disease. Other known
risk factors include cystic fibrosis, chronic obstructive pul-
monary disease (COPD), silicosis, and alpha-1 antitrypsin
deficiency [7–12]. Recent studies have also found an associa-
tion between non-CF bronchiectasis and non-tuberculous
mycobacterial infections [13]. Furthermore, studies suggest
that this association is seen more often in post-menopausal
women.
The association of non-CF bronchiectasis and NTM has
been well described; however, the sequential causality has
been debated and remains to be investigated. In some
patients, bronchiectasis precedes the development of NTM
similar to that seen in patients with cystic fibrosis.
Nonetheless this association is increasingly recognized in tall
thin post-menopausal women. The mechanisms which con-
tribute to the predisposition of women to developing
mycobacterial infections remain to be defined.
Non-CF bronchiectasis and mycobacterial infections
Although the association of non-CF bronchiectasis and NTM
infections has been described regardless of the sequence of
occurrence, there is limited information about the character-
istics of the dual diseases of NTM and non-CF bronchiectasis.
In a recent study, a cohort of patients with adult-onset
bronchiectasis was evaluated to determine the prevalence of
NTM in this group. One hundred and eighty-two patients
diagnosed with non-CF bronchiectasis were included in this
study. NTM was isolated from sputum or bronchoalveolar
lavage (BAL) of 68 (37%) patients.Mycobacterium avium complex
(MAC) was isolated from 81% of patients, Mycobacterium
chelonae from 7%, Mycobacterium kansasii from 3% and other
NTM from 9% of patients. The diagnosis of bronchiectasis
and the isolation of NTM was significantly higher in female
patients and those with low body mass indexes as confirmed
by logistic regression analysis [13].
A study from Japan by Tanaka et al. found a strong associ-
ation between nodular and bronchiectatic changes onchest CT-scan and the isolation of mycobacteria in sputum
or BAL (50% of patients). Interestingly, in their study they
found a female predominance of almost 84% with association
of mycobacterial disease and bronchiectasis (11 out of the 13).
This extreme predominance may be related to the small sam-
ple size and may not be truly reflective of this association; it
nonetheless does suggest an increased predilection for
female patients [14]. A study published by Wickremasinghe
et al. from the United Kingdom showed an association with
NTM in 2% of patients with existing bronchiectasis [15].
However, of note, not all patients in their study had routine
diagnostic tests for NTM from sputum and BAL. Therefore,
it is possible that patients with NTM might have been missed
in their study.
Marras et al. defined the clinical phenotypes of patients
with mycobacterial infections in Toronto, Ontario and found
that 62% of patients with mycobacterial infection had
bronchiectasis with associated centrilobular nodules. It was
not discerned whether bronchiectasis preceded infection
with NTM. However, in those patients who had NTM and
nodular bronchiectasis, they found a predominance of female
patients (74%), whereas patients who had fibrocavitary dis-
ease and NTM were more likely to be male (77%). This study
again suggests a high occurrence of NTM and bronchiectasis
in women [16]. Together these studies suggest an association
of NTM and bronchiectasis and that this association is seen
more often in women.
Gender preponderance in mycobacterial infections
As discussed above, the incidence of NTM is increasing and
several clinical and epidemiologic studies both from the US
and other countries have defined the demographics of
patients with NTM [17,18]. In general, most studies have
found a female preponderance of NTM. Prevots et al. con-
ducted a large population-based estimate of trends in NTM
in the US using American Thoracic Society (ATS) microbio-
logic criteria. Their data was collected between 2004 and
2006 and showed that NTM had surpassed TB in the US with
an increasing prevalence. They found that the prevalence of
NTM was 1.1–1.6-fold higher among women relative to men
across the different sites in the US [2]. In a single site study
in Virginia, Satyanarayan et al. sought to describe the epi-
demiology of mycobacterial infections from 2001 til 2009.
They found that most of the patients were above the age of
60; however, the sex distribution was equal in patients with
NTM (50%) [19].
In a large population-based study in Europe conducted by
NTM-NET collaborative group, an increasing incidence of
NTM with a gender shift was shown with preponderance in
female patients [20]. Studies from New Zealand and
Australia have also shown a similar increase in NTM cases
with a gender shift from middle-aged smoking men to older
non-smoking women [21,22]. They also noted that the
increased susceptibility in women was related to the body
habitus of being tall and thin. Interestingly, a nationwide pop-
ulation study published from Denmark did not show a rise in
the incidence of NTM over a 12-year period; however, they
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nosis. The negative prognostic factors included a high level of
comorbidity, advanced age, male sex, and infection with
Mycobacterium xenopi [23].
In a study from the National Institutes of Health which
enrolled 63 patients with NTM showed that patients with pul-
monary NTM had a characteristic morpho-phenotype. They
found that these patients were taller and leaner than control
subjects with high rates of scoliosis, pectus excavatum, mitral
valve prolapse and cystic fibrosis transmembrane conduc-
tance regulator (CFTR) mutations [24]. A more recent study
by Kartalija et al. investigated the morpho-types of patients
with pulmonary NTM and measured adipokines and cytoki-
nes in these patients. They found that patients with pul-
monary NTM had a distinct body phenotype with increased
scoliosis and pectus excavatum. In addition, they found that
these patients have lower levels of IFN-c and IL-10 with
altered adipokine and leptin levels [25]. In a recent retrospec-
tive study, Lee et al. reviewed patients with pulmonary NTM
between 2005 and 2012. In their study a total of 148 patients
with NTM lung disease and 142 age- and sex-matched con-
trols were enrolled. They found that 60.8% of patients were
women, and patients with both localized disease and exten-
sive NTM disease had less subcutaneous fat compared with
the control group [26].
Together these data suggest that there is compelling evi-
dence for the predisposition of older women with slender
body habitus to NTM. Therefore, the question arises if this
is in some way related to altered sex hormones. In an exper-
imental model, Tsuyuguchi et al. infected ovariectomized
mice with intra-tracheal MAC. They found that the bacterial
burden was significantly higher in ovariectomized mice com-
pared with the sham control. Furthermore, treatment of
ovariectomized mice with exogenous estrogen enhanced the
bacterial clearance [27]. In a study of 35 patients, Danley
et al. measured the levels of dehydroepiandrosterone-
sulfate (DHEA-S), estrone, and ultrasensitive estradiol blood
samples. They found that women with MAC infection had
lower DHEA-S levels, but not lower estrogen levels, compared
with control subjects. There was no relationship between BMI
and hormone levels in their study population. Although the
study makes an interesting observation, the small sample
size makes it difficult to make definitive conclusions [28].
The above studies suggest a role for estrogen in immune
response to NTM. However, the mechanisms by which estro-
gen enhances host defense to NTM remains to be defined. In
an excellent manuscript published by Chan and Iseman, the
contribution of sex hormones and the mechanism by which
they might modulate the NTM response was reviewed. They
hypothesize that hormones such as Luteinizing hormone
(LH) and estrogen may contribute to altered leptin and adipo-
nectin levels that in turn may modulate the host response in
terms of cytokine and chemokine expression (IL-10, TGF-b).
Alternatively, it is plausible that altered leptin and adiponec-
tin levels in thin individuals may contribute to the predispo-
sition to NTM infections [29]. The phenotype of bony
abnormalities and association with mitral valve prolapse
has been hypothesized to abnormal fibrillin levels that in turncan modulate TGF-b expression, although experimental data
to support these findings needs further work.
A recent study from Taiwan by Hseih et al. found Matrix
metalloproteinase-1 (MMP1) polymorphisms among patients
with non-CF bronchiectasis [30]. Their study suggests that
bronchiectasis patients with MMP-1(-1607G) polymorphism
may be more vulnerable to permanent lung fibrosis and/or
airway destruction due to the enhanced MMP-1 and TGF-b1
activity. Another study by Maisi et al. showed that patients
with bronchiectasis had elevated levels of soluble activated
and autocatalyzed Membrane type 1 metalloprotease (MT1-
MMP) species, as well as activated forms of MMP-2 in induced
sputum and bronchoalveolar lavage fluid [31]. Karakoc et al.
measured the levels of MMP-9 from children with CF and
non-CF bronchiectasis from exhaled breath condensates
[32]. They showed that patients with CF and non-CF
bronchiectasis had increased levels of MMP-9 in exhaled
breath condensates. There are studies that have hypothesized
that abnormal production of MMPs may contribute to the tis-
sue destruction seen in subjects infected with M. tuberculosis,
although similar data from NTM patients is scant.
In a recent study, Sakamoto et al. showed that mycobacte-
rial trehalose dimycolate reprograms macrophage global gene
expression and activates matrix metalloproteinases. Of note,
mycobacterial trehalose is a major glycolipid component of
all mycobacteria and therefore similar to M. tuberculsosis
expression of MMPs by NTM andmay contribute to the patho-
genesis of NTM lung disease [33]. Together, these data suggest
that the dual presence of bronchiectasis and NTM may be
related to dysregulation or overproduction of MMPs. It is also
possible that the predilection might be related to polymor-
phisms in genes regulating the production of MMPs [33].
Summary and conclusions
Evidence shows that the incidence of NTM is increasing
worldwide with MAC being the most frequent cause. This
may be the result of improved diagnostics and increased
recognition of the importance of NTM as a causality of lung
disease. The conditions that predispose to NTM have
included chronic lung diseases, such as cystic fibrosis,
COPD, and alpha-1 antitrypsin deficiency; however, associa-
tion with bronchiectasis continues to remain enigmatic.
Whether NTM invade preexisting bronchiectasis or lead to
de novo initiation of bronchiectasis is debatable.
Nonetheless, epidemiologic data have repeatedly suggested
that NTM has a predilection to affect thin, elderly (post-
menopausal) women without underlying lung disease for
unclear reasons. As in this study many of these women also
develop bronchiectasis. Several plausible hypotheses have
been generated to explain these differences, including the
role of sex hormones and mediators, such as leptin and adi-
ponectin, which modulate key cytokines such as TGF-b.
Whether sex hormones truly contribute to these gender dif-
ferences remains to be established, and the mechanisms are
not understood. Fibrillins and matrix metalloproteinases are
other potential mediators that might contribute to the patho-
genesis of dual disease with NTM and bronchiectasis. Further
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the contribution of hormones, mediators and nutritional
status in the immuno-pathogenesis of NTM infections.
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